pharmaceutical industry news from FierceBiotech

A joint venture between Crucell and DSM Biologics - Percivia -- has produced a new, more efficient approach to manufacturing monoclonal antibodies and proteins. By relying on human cell lines rather Read more...

Interest in longevity drugs continues to grow as new research points to the tonic effects of resveratrol. The New York Times notes that some scientists have become so enamored by the potential of the Read more...

A somewhat skeptical Matthew Herper at Forbes did a Q&A with Glaxo's Patrick Vallance on the big news that it's Read more...

Like so many other pharmaceutical industry giants, Roche has announced plans to increase its stake in biotech, Read more...

Responding to the scandal that erupted in the UK following a disastrous early-stage trial Read more...

IBM has inked a $1.4 billion, seven-year deal to manage AstraZeneca's IT infrastructure around the globe. The deal covers everything from PC management to servers and communications. "IBM will Read more...

Press Release: Chinese Pharmaceuticals Market Forecast to Become the World's Fifth Largest by 2010

Read more...

Press Release: Sarasota's Roskamp Institute Discovers New Class of Drugs That Can Impact Alzheimer's Disease

Read more...

Press Release: Consumers and Pharmaceutical Companies Far Apart on Views of Pharma Industry

Read more...

CytRx has set up a subsidiary devoted to RNAi, or gene silencing, and gathered a stellar group of advisers for it that includes the Nobel Prize-winning Craig Mellow. Tod Woolf, the former CEO at Sequitir, will run the operation, dubbed RXi Pharmaceuticals. Other advisers are: Gregory J. Hannon, Tariq M. Rana and Michael P. Czech. CytRx will own 85 percent of the new company and the advisers will share 15 percent.

"The clinical potential of RNAi technology is garnering strong …

Read more...